239 related articles for article (PubMed ID: 33442996)
1. Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma.
Parikh ND; Marshall A; Betts KA; Song J; Zhao J; Yuan M; Wu A; Huff KD; Kim R
J Comp Eff Res; 2021 Apr; 10(5):343-352. PubMed ID: 33442996
[No Abstract] [Full Text] [Related]
2. Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.
Tsang J; Wong JSL; Kwok GGW; Li BCW; Leung R; Chiu J; Cheung TT; Yau T
Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):589-598. PubMed ID: 33666530
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
Yau T; Kang YK; Kim TY; El-Khoueiry AB; Santoro A; Sangro B; Melero I; Kudo M; Hou MM; Matilla A; Tovoli F; Knox JJ; Ruth He A; El-Rayes BF; Acosta-Rivera M; Lim HY; Neely J; Shen Y; Wisniewski T; Anderson J; Hsu C
JAMA Oncol; 2020 Nov; 6(11):e204564. PubMed ID: 33001135
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
Yau T; Zagonel V; Santoro A; Acosta-Rivera M; Choo SP; Matilla A; He AR; Cubillo Gracian A; El-Khoueiry AB; Sangro B; Eldawy TE; Bruix J; Frassineti GL; Vaccaro GM; Tschaika M; Scheffold C; Koopmans P; Neely J; Piscaglia F
J Clin Oncol; 2023 Mar; 41(9):1747-1757. PubMed ID: 36512738
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma.
Juloori A; Katipally RR; Lemons JM; Singh AK; Iyer R; Robbins JR; George B; Hall WA; Pitroda SP; Arif F; Fung J; Pillai A; Liao CY; Sharma M; Liauw SL
Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):202-213. PubMed ID: 36108891
[TBL] [Abstract][Full Text] [Related]
6. Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040).
Sangro B; Yau T; El-Khoueiry AB; Kudo M; Shen Y; Tschaika M; Roy A; Feng Y; Gao L; Aras U
Clin Transl Sci; 2023 Aug; 16(8):1445-1457. PubMed ID: 37165980
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis.
Park S; Nam CM; Kim SG; Mun JE; Rha SY; Chung HC
Eur J Cancer; 2021 Feb; 144():49-60. PubMed ID: 33338727
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of Nivolumab combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis.
Xu Y; Hezam K; Ali MG; Wang Y; Zhang J
Immunopharmacol Immunotoxicol; 2021 Jun; 43(3):386-394. PubMed ID: 34014122
[No Abstract] [Full Text] [Related]
9. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.
Chen J; Wang J; Xie F
Medicine (Baltimore); 2021 Sep; 100(38):e27013. PubMed ID: 34559096
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
[TBL] [Abstract][Full Text] [Related]
11. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.
Pinato DJ; Cortellini A; Sukumaran A; Cole T; Pai M; Habib N; Spalding D; Sodergren MH; Martinez M; Dhillon T; Tait P; Thomas R; Ward C; Kocher H; Yip V; Slater S; Sharma R
BMC Cancer; 2021 Mar; 21(1):301. PubMed ID: 33757459
[TBL] [Abstract][Full Text] [Related]
12. FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib.
Saung MT; Pelosof L; Casak S; Donoghue M; Lemery S; Yuan M; Rodriguez L; Schotland P; Chuk M; Davis G; Goldberg KB; Theoret MR; Pazdur R; Fashoyin-Aje L
Oncologist; 2021 Sep; 26(9):797-806. PubMed ID: 33973307
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies.
Baron K; Moser JC; Patel S; Grossmann KF; Colonna SV; Hyngstrom JR
J Oncol Pharm Pract; 2021 Apr; 27(3):555-559. PubMed ID: 32423325
[TBL] [Abstract][Full Text] [Related]
14. Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer.
Cope S; Keeping ST; Goldgrub R; Ayers D; Jansen JP; Penrod JR; Korytowsky B; Juarez-Garcia A; Yuan Y
J Comp Eff Res; 2019 Jul; 8(10):733-751. PubMed ID: 31237143
[No Abstract] [Full Text] [Related]
15. Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma.
Tachibana H; Kondo T; Ishihara H; Fukuda H; Yoshida K; Takagi T; Izuka J; Kobayashi H; Tanabe K
Jpn J Clin Oncol; 2021 Apr; 51(4):646-653. PubMed ID: 33212488
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment.
Lee CH; Lee YB; Kim MA; Jang H; Oh H; Kim SW; Cho EJ; Lee KH; Lee JH; Yu SJ; Yoon JH; Kim TY; Kim YJ
Clin Mol Hepatol; 2020 Jul; 26(3):328-339. PubMed ID: 32460459
[TBL] [Abstract][Full Text] [Related]
17. A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.
Reinhorn D; Sarfaty M; Leshno M; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Oncologist; 2019 Mar; 24(3):366-371. PubMed ID: 30710066
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis.
Quhal F; Mori K; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Curr Opin Urol; 2022 Jan; 32(1):61-68. PubMed ID: 34720102
[TBL] [Abstract][Full Text] [Related]
20. Indirect comparison of pembrolizumab monotherapy versus nivolumab + ipilimumab in first-line metastatic lung cancer.
Halmos B; Burke T; Kalyvas C; Insinga R; Vandormael K; Frederickson A; Piperdi B
Immunotherapy; 2022 Apr; 14(5):295-307. PubMed ID: 35073727
[No Abstract] [Full Text] [Related]
[Next] [New Search]
